Payment overview · 2025
General Payments
$544.05
35 reported records · 7 companies
Healthcare provider profile · identity verified
Tara S Shields, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSON CITY, TN · NPI 1215347240
Verified facts
What the public records show
CMS Open Payments records show Tara S Shields, MD received $544.05 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 47.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $257.71 | 47.4% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.99 | 33.8% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.15 | 4.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.67 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.69 | 4.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.29 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.55 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $544.05 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $239.66 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $182.12 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $111.93 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.99 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.69 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $12.07 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $8.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 594 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 111 |
| Lisinopril | Lisinopril | 322 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 82 |
| Omeprazole | Omeprazole | 307 | 67 |
| Losartan Potassium | Losartan Potassium | 275 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 264 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 61 |
| Gabapentin | Gabapentin | 227 | 47 |
| Alendronate Sodium | Alendronate Sodium | 217 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 48 |
| Alprazolam | Alprazolam | 173 | 34 |
| Sertraline Hcl | Sertraline Hcl | 170 | 44 |
| Potassium Chloride | Potassium Chloride | 163 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 36 |
| Metformin Hcl | Metformin Hcl | 150 | 32 |
| Eliquis | Apixaban | 132 | 32 |
| Famotidine | Famotidine | 126 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 36 |
| Trazodone Hcl | Trazodone Hcl | 122 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 19 |
| Meloxicam | Meloxicam | 117 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 114 | 25 |
| Lorazepam | Lorazepam | 113 | 18 |
| Furosemide | Furosemide | 109 | 42 |
| Montelukast Sodium | Montelukast Sodium | 101 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 27 |
| Clonazepam | Clonazepam | 94 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 89 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 23 |
| Pregabalin | Pregabalin | 83 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 39 |
| Simvastatin | Simvastatin | 79 | 16 |
| Ezetimibe | Ezetimibe | 77 | 23 |
| Tramadol Hcl | Tramadol Hcl | 74 | 19 |
| Allopurinol | Allopurinol | 69 | 17 |
| Metformin Hcl Er | Metformin Hcl | 68 | 20 |
| Spironolactone | Spironolactone | 67 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 15 |
| Ozempic | Semaglutide | 55 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 13 |
| Glimepiride | Glimepiride | 54 | 13 |
| Ondansetron Odt | Ondansetron | 54 | 17 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Buspirone Hcl | Buspirone Hcl | 52 | 18 |
| Benazepril Hcl | Benazepril Hcl | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 42 |
| Atenolol | Atenolol | 48 | 14 |
| Carvedilol | Carvedilol | 48 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 18 |
| Bupropion Xl | Bupropion Hcl | 45 | 14 |
| Irbesartan | Irbesartan | 42 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 11 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 13 |
| Chlorthalidone | Chlorthalidone | 35 | 11 |
| Linzess | Linaclotide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 13 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 20 |
| Sucralfate | Sucralfate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 26 | 24 |
| Diazepam | Diazepam | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Cefdinir | Cefdinir | 25 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Acyclovir | Acyclovir | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Colchicine | Colchicine | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $544.05 · 35 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, CREON, FARXIGA, LINZESS, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error